Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
116.60
+0.05 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
September 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
September 08, 2021
From
Merck & Co., Inc.
Via
Business Wire
Improving Medical Care in the Black Community With Family Health Histories
September 08, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
September 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
August 31, 2021
From
Merck & Co., Inc.
Via
Business Wire
Employees Help Evacuate Patients From Record Flood in China
August 31, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
August 26, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
August 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Leslie A. Brun Resigns from Merck Board of Directors
August 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
August 19, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Merck Has Been Named One of the Top Employers in New York by Fortune
August 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
August 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Named by Seramount As One of the Best Companies for Multicultural Women
August 11, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
August 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
August 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
August 05, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Has Earned the Top Spot on Forbes' 2021 List of 'Best Employers for New Graduates'
August 04, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
July 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Second-Quarter 2021 Financial Results
July 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Recognized on Best Places to Work for Disability Inclusion List and Received Perfect Score on the Disability Equality Index (DEI)
July 28, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Supply Chain
Exposures
Supply Chain
Merck Announces Fourth-Quarter 2021 Dividend
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
July 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
July 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
VERQUVO® (vericiguat) Approved in the European Union
July 21, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
July 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
July 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.